ZIP. If they run the CV portion of MITIGATE long enough ...say 2 yrs mean length of time in the trial ...and the event lines clearly and consistently diverge ...Dr Nissen or anyone else will have a hard time saying high dose EPA doesn't work in reducing CV event risk ..... in a US population.
They may complain about it being an open label trial , new design etc etc ...but MITIGATE is an older age ( I expect average age over 70 ) , secondary prevention study . The kind of study one would expect to see risk reduction if as we believe it exists.
This is a higher risk population then that in R-IT ...which was about 70% secondary prevention and average age around 66 .
The 12 mth Covid portion ...as per trial design ends on Thursday ...Sept 1st .
Lets see if they have any comment on how long they will do a CV followup for ...Trial is officially supposed to end in Feb 2023
If they dont do a longer term follow up on the CV portion ...tells me they dont want to know. At this stage its minimal cost ...no blood tests , clinic visits ...at most a phone chk in and monitoring of script refills ( all electronic and in house )
Kiwi